Abstract
A series of piperazine ureas was designed, synthesized, and evaluated for their potential as novel orally available fatty acid amide hydrolase (FAAH) inhibitors that are therapeutically effective against pain. We carried out an optimization study of the lead compound 3 to improve its DMPK profile as well as in vitro potency. We identified the thiazole compound 60j with potent inhibitory activity, high brain permeability, and good bioavailability. Compound 60j showed a potent and dose-dependent anti-nociceptive effect in the acetic acid-induced writhing test in mice.
Copyright © 2012 Elsevier Ltd. All rights reserved.
MeSH terms
-
Amidohydrolases / antagonists & inhibitors*
-
Amidohydrolases / metabolism
-
Analgesics / chemistry*
-
Analgesics / pharmacokinetics
-
Analgesics / therapeutic use*
-
Animals
-
Humans
-
Mice
-
Molecular Docking Simulation
-
Pain / drug therapy
-
Pain / enzymology
-
Piperazine
-
Piperazines / chemistry*
-
Piperazines / pharmacokinetics
-
Piperazines / therapeutic use*
-
Rats
-
Structure-Activity Relationship
-
Thiazoles / chemistry
-
Thiazoles / pharmacokinetics
-
Thiazoles / therapeutic use
-
Urea / analogs & derivatives*
-
Urea / pharmacokinetics
-
Urea / therapeutic use*
Substances
-
Analgesics
-
Piperazines
-
Thiazoles
-
Piperazine
-
Urea
-
Amidohydrolases
-
fatty-acid amide hydrolase